Background 35% of patients with pancreatic cancer have unresectable locally advanced
disease at diagnosis. Several studies have examined systemic chemotherapy with …

Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …

Objective: For patients with locally advanced and unresectable pancreatic cancer (PDAC),
neodadjuvant treatment and consecutive surgical exploration have been studied during the …

Chemotherapy is an important part of multimodality pancreatic cancer treatment. After
curative resection, adjuvant chemotherapy can significantly improve disease free survival …

Objective: Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with
pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary …

Background Treatment options for patients with unresectable locally advanced pancreatic
cancer are scarce. Results from a subanalysis of the phase 3 MPACT trial in metastatic …

Background The prognosis of pancreatic cancer (PaC) strongly varies across different
stages and age groups, which has unfortunately not been well recorded in the literature …

Background The purpose of this study was to evaluate a single-institution experience with
delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) …

Introduction: Vascular resection remains a subject of debate in the management of
Pancreatic Ductal Adenocarcinoma (PDAC). These French recommendations were drafted …

Background Pancreatic cancer has been and still is associated with a very poor prognosis.
This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication …